AbbVie's AGN-151586 Phase 2 forehead lines study completes enrollment; four more trials registered

AbbVie's registry activity for the week includes one trial moving to active status and four newly registered or continuing studies.

• A Phase 2 trial of AGN-151586, also known as trenibotulinumtoxinE, evaluating safety and efficacy for moderate to severe forehead lines in adults¹ is now active, not recruiting, with enrollment of 84 participants (actual)¹. The study tracks adverse events over approximately 42 days¹, with primary completion estimated for October 2026.
• A new Phase 4 study called AURA (NCT07794891) is recruiting to evaluate subject satisfaction and psychosocial outcomes after treatment of jawline and neck with BOTOX Cosmetic and JUVÉDERM products². The trial plans to enroll 100 participants² and began 2026-09-09, with primary completion estimated June 2027.
• AbbVie is a collaborator, not the lead sponsor, on ATUNE, a Phase 2 trial run by the University of North Carolina, Chapel Hill testing whether upadacitinib can help treat eosinophilic esophagitis, specifically whether it added to topical corticosteroids helps reduce disease activity³. The study is recruiting, with enrollment of 52 participants³ estimated.
• AbbVie registered a post-marketing observational study (NCT07862764) in Korea to assess adverse events and change in disease activity in adult Korean participants with DLBCL under routine clinical practice⁴ who are prescribed epcoritamab. The study is not yet recruiting, with approximately 175 adult participants⁴ planned and an estimated start of 2026-10-02.
• AbbVie's Phase 1 trial of ABBV-7828 (NCT07856706), assessing safety, tolerability, pharmacokinetics and food effect in healthy adult participants⁵, remains not yet recruiting, with an estimated start of 2026-09-21 and planned enrollment of 60 participants⁵.